Clinical trials: Cancer of the Fallopian Tube
Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
This phase I trial studies the side effects and best dose of activated T-cell therapy when given together with low-dose aldesleukin and sargramostim in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02470559
- Testing
- Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer, Fallopian Tube Cancer
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Patients who have this kind of cancer are often treated with several drugs. Carboplatin is one that seems to work for many treatment cycles. Even though it may work against the cancer, the patient can become allergic to it.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01248962
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to…
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
- Trial name
- NCT02785250
- Testing
- DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
- Where
- 9 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Ovarian Cancer
ICON8: Weekly Chemotherapy in Ovarian Cancer
The purpose of this study is to determine if weekly chemotherapy (i.e. giving paclitaxel or carboplatin at a lower dose every week) is more effective than standard chemotherapy (paclitaxel and carboplatin given once every three…
- Trial name
- ICON8 (NCT01654146)
- Testing
- Carboplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 1,485 people
- Sponsor
- Medical Research Council
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06161272
- Testing
- Fluzoparib, Fluzoparib+Apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangxi Medical University
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03029598
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Ovarian Cancer, Fallopian Tube Cancer
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01669798
- Testing
- BIBF 1120
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- AA Secord
Ovarian Cancer, Fallopian Tube Cancer
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary Objective: 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125)…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00634894
- Testing
- Femara
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes after treatment, the tumor may not need additional treatment until it progresses.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00263822
- Testing
- erlotinib hydrochloride
- Where
- 92 sites in Australia, Austria and 6 more
- Volunteers
- 835 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for…
- Trial name
- ASPENOVA (NCT07546500)
- Testing
- Investigator's choice of Chemotherapy, Azenosertib
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Ovarian Cancer, High Grade Serous Carcinoma
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
In BriTROC-2, up to 250 women with a confirmed diagnosis of high-grade serous/high-grade endometrioid or carcinosarcoma will be eligible for full consent (Part 2) and registration to BriTROC-2 and will be followed prospectively…
- Conditions
- Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer
- Trial name
- BriTROC-2 (NCT05537844)
- Where
- 11 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Liz-Anne Lewsley
Ovarian Cancer, Primary Peritoneal Cancer
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01196559
- Testing
- Vinorelbine and Gemcitabine
- Where
- 4 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- The Catholic University of Korea
Ovarian Cancer, Fallopian Tube Cancer
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- PROMPT (NCT03430700)
- Testing
- Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Advanced Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib.
- Trial name
- NCT05949632
- Testing
- INCB099280, axitinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Ovarian Cancer, Fallopian Tube Carcinoma
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group.
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06290193
- Testing
- Acute Normovolemic Hemodilution/ANH
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01100372
- Testing
- gemcitabine hydrochloride, liposome-encapsulated doxorubicin citrate, quality-of-life assessment
- Where
- Austria
- Volunteers
- 154 people
- Sponsor
- Medical University Innsbruck
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal…
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT05415709
- Testing
- Carboplatin, Cisplatin, Cytoreductive Surgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, HGSOC
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer.
- Conditions
- Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Trial name
- OVACT (NCT07665515)
- Testing
- CryptiVax-1001
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Epitopea Ltd
Ovarian Cancer
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian…
- Trial name
- NCT05983276
- Testing
- Decitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Loyola University